吉非替尼改善晚期非小细胞肺癌患者生活质量的临床研究

Clinical analysis of gefitinib for improving quality of life in patients with advanced non-small cell lung cancer

目的评价吉非替尼对非小细胞肺癌患者生活质量的影响。方法对68例应用吉非替尼的非小细胞肺癌患者治疗前后生活质量进行统计学分析,生活质量分析采用欧洲癌症研究和治疗组织(European Organization for Research and Treatment of Cancer,EORTC)简体中文版EORTCQLQ-C30和QLQ-LC13问卷对治疗前、后症状和生活质量的改变进行评价。结果68例患者完成了问卷调查。治疗后患者5种功能状态(躯体、角色、情感、认知、社会)及整体生活质量评分均值显著增加,与治疗前相比差异有显著性(P<0.05)。治疗后乏力症状评分的均值显著降低,与治疗前相比差异有显著性(P<0.05),治疗后肺癌相关症状(咳嗽、胸痛、呼吸困难)评分的均值显著降低,与治疗前相比差异有显著性(P<0.05)。症状和生活质量的改善与疾病控制相一致。生活质量改善者生存延长。结论吉非替尼可改善晚期非小细胞肺癌患者的症状和生活质量。

Objective To appraise the influence of gefitinib quality of life of the non-small cell lung cancer patient.Methods Sixty-eight non-small cell lung cancer patients were treated with gefitinib.Before and after treatment,the quality of life of the patients was evaluated with the Chinese versions of European Organization for Research and Treatment of Cancer Quality of Life Questionnaires（EORTC QLQ-C30 and QLQ-LC13）.Results Sixty-eight patients finished the questionnaires.Compared with the mean scores before treatment,the mean scores of five functional scales（physical,role,emotional,cognitional and socia1） and the mean score of global QoL were improved after treatment,with statistically significant differences（P0.05）.The mean scores of main general symptom fatigue decreased compared with before treatment,and the mean scores of disease-related symptoms（cough,chest pain,dyspnea）decreased after treatment,with statistical differences in fatigue,dyspnea,cough and chest pain（P0.05）.Both QoL and symptom response were correlated with disease contro1.The patients with better QoL had longer survival time.Conclusion Gefitinib treatment could improve the QoL and symptoms of advanced NSCLC patients.